Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01478477 · ClinicalTrials.gov registry record · NA
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT01478477 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 44 participants.
The verdict
NCT01478477, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
This randomized pilot trial studies omega-3 fatty acid in preventing joint symptoms in patients with stage I-III breast cancer receiving anastrozole, exemestane, or letrozole. Omega-3 fatty acid supplement may lessen or prevent joint stiffness or pain in patients receiving hormone therapy for breast cancer.
Interventions
- OTHER Placebo
- PROCEDURE Magnetic Resonance Imaging
- DIETARY_SUPPLEMENT omega-3 fatty acid supplement
- OTHER Clinical assessments
- OTHER Assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-10-04 |
| Est. Completion | 2014-01-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01478477
The ClinicalTrials.gov registry entry for NCT01478477 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01478477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01478477 about?
NCT01478477 is a clinical study titled "Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole". This randomized pilot trial studies omega-3 fatty acid in preventing joint symptoms in patients with stage I-III breast cancer receiving anastrozole, exemestane, or letrozole. Omega-3 fatty acid supplement may lessen or prevent joint stiffness or pain in patients receiving hormone therapy for breast...
What is the current status of trial NCT01478477?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2011-10-04. Estimated completion is 2014-01-09.
What interventions are being tested in trial NCT01478477?
The interventions under investigation include: Placebo (OTHER), Magnetic Resonance Imaging (PROCEDURE), omega-3 fatty acid supplement (DIETARY_SUPPLEMENT), Clinical assessments (OTHER), Assessment of therapy complications (OTHER).
Who is sponsoring clinical trial NCT01478477?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.